Evaluating the Effect of Volten VR4® Kaempferia parviflora Extracts on Blood Glucose Levels in Human Type-2 Diabetes Mellitus and Healthy Individual: A Case-Control Study

2021 ◽  
Vol 104 (10) ◽  
pp. 1610-1616
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Control Group ◽  
Kaempferia Parviflora ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Patients With Diabetes

Background: Volten VR4® capsules contain extract of Kaempferia parviflora (KP), which has been claimed to reduce blood glucose in patients with diabetes. Objective: To evaluate the efficacy of Volten VR4® on healthy individuals and Type-2 Diabetes Mellitus volunteers. Materials and Methods: The extracts of 400 mg capsules of KP were consumed for five days. The fasting and blood glucose levels of 2-hour postprandial were measured at baseline and day 5. A group of 15 healthy young adults between the age of 20- and 30-years old were the control group of the present study, while 12 volunteers aged 35 to 75 years old diagnosed with Type-2 Diabetes Mellitus constituted the experimental group. Data were validated through the Willcoxon and Friedman test statistics and error distribution. Results: It had been shown that the specificity of KP reduced blood glucose levels and has associated with the flavonoids and polymethoxyflavones components. The results showed that consuming VR4® capsules significantly reduced blood glucose, either at the state of fasting or postprandially in diabetic individual. Conclusion: Volten VR4® Kaempferia parviflora extract is safe to be consumed at 400 mg at one time. The study also has shown that the participants are free from adverse reactions and hypoglycaemia. Keywords: Kaempferia parviflora; Blood glucose; Type-2 Diabetes Mellitus; Flavonoids; Polymethoxyflavones; Hypoglycemia and heavy metal elements

scholarly journals THE INFLUENCE OF EDUCATION OF DRUG INFORMATION BY PHARMACIST ON THE IMPROVEMENT OF KNOWLEDGE AND THERAPEUTIC TARGET TO TYPE 2 DIABETES MELLITUS OUTPATIENTS IN HOSPITAL

2017 ◽  
Vol 9 (3) ◽  
pp. 199
Author(s):  
Puji Asmini
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Therapeutic Target ◽  
Drug Information ◽  
Control Group ◽  
Glucose Levels ◽  
Blood Glucose Levels

Objective: The study aims to determine the influence of education of drug information by the pharmacist on the improvement of knowledge and therapeutic target to type 2 diabetes mellitus outpatients in Dr. Moewardi Surakarta Hospital.Methods: The research used the quasi-experimental method, repeated measure experiment design, pre-posttest design with the prospective patient data retrieval. 90 patients with type 2 diabetes mellitus were used as the subjects of the research divided into three groups (two test groups and one control group). In the test1 group, patients were educated about the drug information through leaflets and through oral explanation, the test 2 group through leaflets, and a control group through leaflets once at the beginning of the study. The study lasted for three months in which in every month fasting blood glucose levels (FBG) and blood glucose levels were analyzed within two hours after a meal (BG2PP) and given questionnaires knowledge to see the socio-demographic profile, knowledge, and blood glucose level of the patient. The data analysis used the statistical package for social sciences (SPSS) version 16 in the form of analysis Kolmogorov-Smirnov test and one-way anova test.Results: The results showed that the education of the drug information by a pharmacist using leaflets and oral explanation in the test1 group was able to improve knowledge of type 2 diabetes mellitus outpatients in Dr. Moewardi Surakarta Hospital, in comparison to the leaflets giving information only to the test 2 group and control group. The education of drug information on the test 1 group was able to improve the patients' knowledge reaching 100%. Type 2 diabetes outpatients in the test 1 group could achieve a reduction in blood sugar levels, to the FBG level (136.47±36.08) mg/dl and BG2PP levels (193.43±58.21) mg/dl.Conclusion: The education of drug information from the pharmacist had the influence to improves the knowledge and therapeutic target of type 2 diabetes mellitus outpatients in Dr. Moewardi Surakarta Hospital.

scholarly journals Pengaruh Akupresur terhadap Kadar Glukosa Darah Pasien Diabetes Melitus Tipe 2 di Persadia RS Islam Jakarta Cempaka Putih

2019 ◽  
Vol 1 (1) ◽  
pp. 38-50
Author(s):  
Jumari Jumari ◽  
Agung Waluyo ◽  
Wati Jumaiyah ◽  
Dhea Natashia
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Control Group ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Reduce Blood Glucose

However limited study had examined the effect of acupressure to reduce blood glucose levels in patients with type 2 diabetes mellitus. This quasi experimental trial was conducted to identify the effect of acupressure on blood glucose level in patients with type 2 diabetes mellitus. Purposive samples of 32 patients were enrolled. They were divided into intervention (n = 16) and control group (n = 16). Paired t-test have been used to examine the effectiveness of acupressure before and after intervention. The results showed a significant difference in blood glucose levels between the intervention group and the control group (t = 4.22; p = 0.001). Acupressure is an effective intervention to reduce blood glucose levels in patients with type 2 diabetes mellitus. Acupressure can be recommended as one of the independent complementary therapies in nursing care among patient with type 2 diabetes mellitus.   Keywords: Acupressure, Blood Glucose Level, Type 2 Diabetes Mellitus.

scholarly journals THE EFFECT OF TAPPING THERAPY ON BLOOD GLUCOSE LEVELS IN TYPE 2 DIABETES MELLITUS PATIENTS AT PURWOKERTO

2018 ◽  
Vol 1 (1) ◽  
pp. 93
Author(s):  
Atyanti Isworo ◽  
Wahyu Ekowati
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Nursing Intervention ◽  
Wilcoxon Test ◽  
Control Group ◽  
Glucose Levels ◽  
Blood Glucose Levels

Introduction: Diabetes Mellitus (DM) is a chronic metabolic disease that can lead to microvascular and macrovascular complications. This condition makes DM patients at higher risk of experiencing stress. Tapping Therapy is one of nursing intervention that can reduce stress. The purpose of this study was to identify the effect of tapping therapy on blood glucose levels in Primary Health Center South Purwokerto. Methods: This research was a quantitative with a quasi experimental with control group, recruited 30 respondents, consisted of 15 respondents who were trained on tapping therapy, one time daily for 30 minutes for four weeks and the other respondents were as the control group. The purposive sampling was used as the sample collection method. Wilcoxon test was employed to examine the differences of the mean of blood glucose levels between intervention and control groups. Results. The result revealed that there was a significant difference of blood glucose levels before and after treatment in intervention group (p = 0.003, α =0.05). Discussion: The conclusion was that the tapping therapy can decrease blood glucose level on type 2 diabetes mellitus patients at Purwokerto. This research recommendation was to apply tapping therapy to patient with diabetes mellitus at least one time daily for 30 minute. Keyword: blood glucose, diabetes, tapping therapy

scholarly journals Pharmaceutical hit of anti type 2 Diabetes mellitus on the phenolic extract of Malaka (Phyllanthus emblica L.) flesh

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Musri Musman ◽  
Mauli Zakia ◽  
Ratu Fazlia Inda Rahmayani ◽  
Erlidawati Erlidawati ◽  
Safrida Safrida
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Phyllanthus Emblica ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Phenolic Extract

Abstract Background Ethnobotany knowledge in a community has shaped local wisdom in utilizing plants to treat diseases, such as the use of Malaka (Phyllanthus emblica) flesh to treat type 2 diabetes. This study presented evidence that the phenolic extract of the Malaka flesh could reduce blood sugar levels in the diabetic induced rats. Methods The phenolic extract of the P. emblica was administrated to the glucose-induced rats of the Wistar strain Rattus norvegicus for 14 days of treatment where the Metformin was used as a positive control. The data generated were analyzed by the two-way ANOVA Software related to the blood glucose level and by SAS Software related to the histopathological studies at a significant 95% confidence. Results The phenolic extract with concentrations of 100 and 200 mg/kg body weight could reduce blood glucose levels in diabetic rats. The post hoc Dunnet test showed that the administration of the extract to the rats with a concentration of 100 mg/kg body weight demonstrated a very significant decrease in blood glucose levels and repaired damaged cells better than administering the extract at a concentration of 200 mg/kg weight body. Conclusion The evidence indicated that the phenolic extract of the Malaka flesh can be utilized as anti type 2 Diabetes mellitus without damaging other organs.

scholarly journals Study on the prevalence of dyslipidemia in type 2 diabetes mellitus

2019 ◽  
Vol 6 (3) ◽  
pp. 786
Author(s):  
Eda Dayakar ◽  
C. Sathya Sree ◽  
E. Sanjay
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Diabetic Patients ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Type 2 Diabetic

Background: Diabetes mellitus is a common health problem globally. Dyslipidaemia is a major risk factor to develop cardiovascular disease in diabetics. They present study was undertaken to find out the prevalence of dyslipidaemia in type 2 diabetic patients.Methods: The present study was a cross sectional study consisting of 46 (23 male and 23 female) known type 2 diabetes mellitus patients. Age, gender, duration of diabetes, body mass index (BMI) was recorder in all the diabetic patients.  Fasting blood glucose levels, total cholesterol, triglycerides, HDL, LDL, VLDL levels were measured using standard methods and recorded.Results: The average total cholesterol, triglycerides, LDL, HDL and VLDL were 200±42mg/dl, 169.62±89.79mg/dl, 132.45±36.38mg/dl,39.1±16.6mg/dl and 35.85±17.09mg/dl respectively. The incidence of occurrence of hypercholesterolemia was 58.6% and hypertriglyceridemia 36.9%. Increased levels of LDL were observed in 30 (65.2%) patients and reduced HDL was observed in 43 (93.4%) patients. The incidence rate of dyslipidaemia was higher in female diabetic patients when compared to male diabetic patients.Conclusions: Awareness on the dyslipidaemia and its risk factors should be provided to the type 2 diabetic patients as they are more prone to get cardiovascular disease and lipid profile also should be monitored regularly along with blood glucose levels.

Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

2011 ◽  
Vol 3 ◽  
pp. CMT.S6227 ◽  
Author(s):  
Kathryn MS Johnson ◽  
Kathleen Schurr
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Diabetes Therapy ◽  
High Blood Glucose ◽  
Adverse Side Effects ◽  
Glucose Levels ◽  
Blood Glucose Levels

Type 2 diabetes mellitus (T2DM) has become an epidemic, with worldwide projections indicating that more than 336 million people will be afflicted with the disease by 2030. T2DM is characterized by inappropriately high blood glucose levels due to a deficiency in insulin secretion, action, or both. Despite the horrific complications that occur with chronic elevations of blood glucose levels, less than half of those with T2DM do not maintain proper glycemic control. Sitagliptin (Januvia, Merck and Co., Whitehouse Station, New Jersey) is a novel diabetes therapy approved for use in the U.S. and Europe. This small molecule inhibits the activity of DPP-4, a peptidase that degrades the glucoregulatory hormone GLP-1. Sitagliptin increases glucoregulation in individuals with T2DM both as a monotherapy and in combination with other antihyperglycemic drugs, with a low risk of adverse side effects.

Sign in / Sign up

Export Citation Format

Share Document